|
|
|
|
|||||
|
|
|
Cellebrite topped Wall Street's sales and earnings expectations for the third quarter.
The company also raised its full-year guidance.
Cellebrite (NASDAQ: CLBT) stock is soaring in Thursday's trading. The company's share price had risen 22.7% as of 12:30 a.m. ET on the back of strong earnings results.
Cellebrite published its third-quarter results after yesterday's market close, delivering sales and earnings for the period that topped expectations. The company also issued strong forward guidance.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »
Image source: Getty Images.
Cellebrite reported non-GAAP (generally accepted accounting principles) adjusted earnings per share of $0.01 on revenue of $126.03 million in the third quarter. The company's per-share profit beat the average analyst target by $0.01, and sales in the period beat the average Wall Street forecast by roughly $3 million. The business's sales were up nearly 18% year over year in the period, and sales from its subscription service improved by 21% compared to last year's quarter.
On the heels of its strong Q3 performance, Cellebrite raised some of its full-year performance targets. The company now expects full-year sales to be between $470 million and $475 million -- up from its previous target for revenue between $460 million and $475 million. Management also raised its target for annualized recurring revenue (ARR) to between $460 million and $475 million -- up from its previous forecast for ARR between $435 million and $445 million. Notably, the new forecasts due not include potential contributions from the company's pending acquisition of Corellium.
Cellebrite saw some significant wins among customers in its U.S. Federal segment, and it anticipates renewed growth in the category next year. The company also sees significant room for portfolio expansion and growth among private-sector customers in conjunction with the expected closing of its acquisition of Corellium in the current quarter.
Before you buy stock in Cellebrite, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Cellebrite wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $624,230!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,187,967!*
Now, it’s worth noting Stock Advisor’s total average return is 1,069% — a market-crushing outperformance compared to 195% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.
*Stock Advisor returns as of November 10, 2025
Keith Noonan has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Cellebrite. The Motley Fool has a disclosure policy.
| Nov-13 | |
| Nov-13 | |
| Nov-13 | |
| Nov-12 | |
| Nov-12 | |
| Nov-10 | |
| Nov-10 | |
| Nov-06 | |
| Nov-05 | |
| Oct-30 | |
| Oct-29 | |
| Oct-28 | |
| Oct-22 | |
| Oct-17 | |
| Oct-15 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite